TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04098484

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Trial
Description: Participants will abstain from exercise throughout a 3-month period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Trial
Description: Participants will abstain from exercise throughout a 3-month period

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Trial
Description: Participants will execute a 3-month exercise training program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Trial
Description: Participants will execute a 3-month exercise training program
Study: NCT01940172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birinapant
Description: Dose Escalation:~Dose Level (1) - 13 mg/m2 (twice a week for 3 of 4 weeks); Dose Level (-1) - 11 mg/m2 (twice a week for 3 of 4 weeks); Dose Level (2) - 13 mg/m2 (twice weekly for 4 weeks );

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conatumumab
Description: 10 mg/kg IV on Day 1 and 15 of each cycle
Study: NCT01712724

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: combined resistance and aerobic training
Description: For the group randomized to AT+RT, Patients will gradually be progressed from 1-2 sets and then from 10-15 repetitions and then increase resistance by 1.6-5 kg or increase the exercise band level and then reduced repetitions to 10 and repeated this process.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combined resistance and aerobic training
Description: For the group randomized to AT+RT, Patients will gradually be progressed from 1-2 sets and then from 10-15 repetitions and then increase resistance by 1.6-5 kg or increase the exercise band level and then reduced repetitions to 10 and repeated this process.
Study: NCT01598129

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ONCOS-102
Description: GMCSF encoding 3/5 chimeric adenovirus for intratumoral and intravenous injection on day 1, 4, 8, 15, 29, 57, 85, 113 and 141 tested in three different dose cohorts (3x10E10, 1x10E11 and 3x10E11) in combination with low-dose metronomic cyclophosphamide.
Study: NCT00918736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium hyaluronate
Description: 3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hyalgan) into the ankle joints.
Study: NCT00838084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2811376
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2811376
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2811376
Description: Oral capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsules
Study: NCT01991613

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: liquid protein supplement
Description: The liquid protein supplement is already in use. The purpose of this study is to determine whether using the supplement earlier will lead to improved growth.
Study: NCT02661048

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CyberHeart System
Description: The CyberHeart system uses proprietary software to assist the cardiologist to contour ablation targets. Standard radiosurgical techniques are then used to accomplish ablation
Study: NCT01251341

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Based Compassion Training
Description: Eight-week training in compassion meditation, using a protocol developed by Geshe Lobsang Negi, Ph.D. of Emory University

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Attention Training
Description: Eight week training in mindful attention, using a protocol developed by B. Alan Wallace, Ph.D.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adult Health Education Curriculum
Description: Eight week training in health and wellness, using a curriculum developed specifically for this study.
Study: NCT02303132

Intervention type: OTHER
Group type: OTHER
Intervention: Ussing experiment
Description: fresh colon mucosa (biopsy) of all participants will be mounted in an Ussing chamber and exposed to NSAIDs / PPI / control.

Intervention type: OTHER
Group type: OTHER
Intervention: Ussing experiment
Description: fresh colon mucosa (biopsy) of all participants will be mounted in an Ussing chamber and exposed to NSAIDs / PPI / control.

Intervention type: OTHER
Group type: OTHER
Intervention: Ussing experiment
Description: fresh colon mucosa (biopsy) of all participants will be mounted in an Ussing chamber and exposed to NSAIDs / PPI / control.
Study: NCT02028208

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ammoniated mercury
Description: Metal allergen panel containing ascending doses of ammoniated mercury and a negative control.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Aluminum chloride and aluminum lactate
Description: Metal allergen panel containing ascending doses of alumium chloride, aluminum lactate and a negative control.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sodium tetrachloropalladate
Description: Metal allergen panel containing ascending doses of sodium tetrachloropalladate and a negative control.
Study: NCT02837107

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mind Master
Description: 80ml Mind Master / day for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 80ml a look-alike Placebo / day for 8 weeks
Study: NCT01961726

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Coronary Sinus Delivery

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Coronary Sinus Delivery

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30 mg dose of JVS-100
Description: Coronary Sinus Delivery

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 30 mg dose of JVS-100
Description: Coronary Sinus Delivery
Study: NCT02989519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micronized progesterone
Study: NCT03667703

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famotidine
Description: Patients will be randomized to either receive a placebo or famotidine (study drug).
Study: NCT01961726

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 45 mg dose of JVS-100
Description: Coronary Sinus Delivery

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 45 mg dose of JVS-100
Description: Coronary Sinus Delivery
Study: NCT02609867

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flowise Cerebral Flow Diverter
Description: Flowise Cerebral Flow Diverter Placement
Study: NCT01914341

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Live music played on the pentatonically tuned children's harp
Study: NCT02637349

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POST Intervention
Description: POST Intervention group will receive a tailored survivorship care plan (SCP) at the end of their active treatment. The SCP will be discussed with them. Patient will be asked about satisfaction with the end of treatment session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: POST Treatment as Usual
Description: The POST control group may receive a survivorship care plan (SCP) as part of treatment as usual though it is not a usual procedure. They will be asked about their satisfaction with the end of treatment session.
Study: NCT03679520

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New programme
Description: Time for topics related to the time after birth and in reversed chronological order to give an early and joint focus on parenthood for both parents. Involving new parents to share their experiences of early parenthood with expectant parents. Introducing and using evidence-based websites in the sessions A breastfeeding preparation that gives tools to meet common challenges in the initial phase of breastfeeding. Based on principles for adult learning.~Sessions~1. Introduction, life-change of becoming a parent and co-parenting~2. Early parenthood~3. Breastfeeding, caring for the baby and early parenthood~4. and 5 Labour, birth and postnatal care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular programme
Description: Antenatal parental preparation as usual. As no guidelines exist the number of sessions may vary between 2 and 3 sessions and smaller variations in content may also occur.~Sessions~1. (or 1 and 2) Labour, birth and postnatal care~2. or 3 Breastfeeding, caring for the baby and early parenthood
Study: NCT01903980

Intervention type: OTHER
Intervention: No intervention. It is a retrospective study
Description: No intervention. It is a retrospective study
Study: NCT01641419

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 ml of saline added to 30 ml of ropivacaine 0.5% solution for nerve block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 4 mg
Description: 2 ml of dexamethasone 4 mg solution added to 30 ml of ropivacaine 0.5% solution for nerve block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 8 mg
Description: 2 ml of dexamethasone 8 mg solution added to 30 ml of ropivacaine 0.5% solution for nerve block
Study: NCT03667703

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be randomized to either receive a placebo or famotidine (study drug).
Study: NCT00311467

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine, Interferon, Interleukin
Description: Capecitabine orally from day 1 to 14 at a dose of 1000 mg/m2 twice daily every 21 days.~Interferon-alpha subcutaneously on days 1 + 3 + 5 weeks 1 + 2 +6 + 7,11+12 at a dose of 6 MIU/d.~Interleukin-2 subcutaneously on days 1 to 4 in weeks 3 + 4 +8 + 9,13+14 at a dose of 4.5 MIU/day.~Group B~Patients randomized to group B will receive treatment according to the same treatment schedule and at the same dosages without capecitabine.~Efficacy evaluations will be performed every 14 weeks of treatment in both groups

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine, Interferon, Interleukin
Description: Capecitabine orally from day 1 to 14 at a dose of 1000 mg/m2 twice daily every 21 days.~Interferon-alpha subcutaneously on days 1 + 3 + 5 weeks 1 + 2 +6 + 7,11+12 at a dose of 6 MIU/d.~Interleukin-2 subcutaneously on days 1 to 4 in weeks 3 + 4 +8 + 9,13+14 at a dose of 4.5 MIU/day.~Group B~Patients randomized to group B will receive treatment according to the same treatment schedule and at the same dosages without capecitabine.~Efficacy evaluations will be performed every 14 weeks of treatment in both groups
Study: NCT03395379

Intervention type: PROCEDURE
Intervention: RFA
Description: Radiofrequency ablation (RFA) is a medical procedure in which part of the electrical conduction system of the tumor is ablated using the heat generated from medium frequency alternating current.

Intervention type: PROCEDURE
Intervention: RFA
Description: Radiofrequency ablation (RFA) is a medical procedure in which part of the electrical conduction system of the tumor is ablated using the heat generated from medium frequency alternating current.
Study: NCT06517134

Intervention type: DRUG
Intervention: Antihypertensive Agents
Description: use of antihypertensive drugs
Study: NCT01843855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin 9,39
Description: Exendin 9,39 is a competitive antagonist of endogenous GLP-1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A saline infusion will be given to match the study drug infusion.
Study: NCT00868101

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Description: Remote ischemic preconditioning was induced by four 5-minutes cycles of lower limb ischemia and reperfusion using a blood pressure cuff
Study: NCT03715283

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Ankle Strengthing Program
Description: Patients in this arm will be given a USB or DVD video with description of ankle dorsi- and plantar- flexion resistance band exercise. They will also be given an outlined plan for there exercises, progression and an exercise diary. In general patients will start with a low resistance and low reps, over the 4 weeks they will increase the repetitions at the same resistance band. After the 4 weeks they will have the option to escalate the band resistance or continue at the same resistance and repetitions until comfortable progressing. The same 4 week progression will be used for each resistance band over the 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Patients in this arm will be directed to continue there standard care program. They will be asked to refrain from resistance exercise for 12 weeks.
Study: NCT01459705

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure Therapy (PE)
Description: Prolonged exposure therapy will consist of 10 treatment sessions lasting 90 - 120 minutes each, with additional between-session homework assignments.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy (VRET)
Description: Virtual Reality Exposure Therapy will consist of 10 treatment sessions lasting 90 -120 minutes with additional between-session homework assignments.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Waitlist
Description: This group will refrain from psychotherapy until after the completion of the 5 weeks of study participation
Study: NCT03777683

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement (OLIGOPIN)
Description: investigators obtained ethical approval from the Research Ethics Committees of the Mashhad University of medical sciences. investigators enroll 60 patients who are admitted to ICU at hospitals of university. All eligible patients or their first degree relatives give informed consent before participating. Participants are randomly (block stratification) divided in two groups. At the first visit, baseline data are gathered and intervention group (n=30) will receive Oligopin supplement. In order to control the confounding effect of food intake, both the control and the intervention group receive the standard formulas based on their daily required energy via enteral root feeding.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: investigators obtained ethical approval from the Research Ethics Committees of the Mashhad University of medical sciences. investigators enroll 60 patients who are admitted to ICU at hospitals of university. All eligible patients or their first degree relatives give informed consent before participating. Participants are randomly (block stratification) divided in two groups. At the first visit, baseline data are gathered and control group (n=30) will receive oral capsules containing 130 mg Microcrystalline Cellulose. In order to control the confounding effect of food intake, both the control and the intervention group receive the standard formulas based on their daily required energy via enteral root feeding.
Study: NCT01276236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: FDA Recommended dosing will be used in this study. Subjects on an efavirenz or etravirine-based regimen will be dosed at 600 mg orally, twice per day, for 96 weeks.~Subjects on a ritonavir-boosted protease inhibitor based regimen (except for tipranavir/ritonavir) will be dosed at 150 mg orally, twice per day, for 96 weeks.~Subjects that are on regimens that do not include etravirine, efavirenz, or ritonavir will be dosed at 300mg orally, twice per day, for 96 weeks. These doses are based on the recommendations from the company based on drug-drug interactions.
Study: NCT05836376

Intervention type: PROCEDURE
Intervention: Mitral valve annuloplasty
Description: implantation of a prosthetic ring to treat mitral valve regurgitation

Intervention type: PROCEDURE
Intervention: Mitral valve annuloplasty
Description: implantation of a prosthetic ring to treat mitral valve regurgitation
Study: NCT00845988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aripiprazole
Description: dosage form : po recommended dosage : more than 10mg/day duration : 28 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aripiprazole
Description: dosage form : po recommended dosage : more than 10mg/day duration : 28 weeks
Study: NCT03034395

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Wide Local Excision
Description: Surgery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Wide Local Excision
Description: Surgery
Study: NCT03262415

Intervention type: DEVICE
Intervention: LabPatch Continuous Glucose Monitoring (CGM)
Description: 1. The patch device that will be applied to subjects' arms in this study is about 3 inches in length and one inch in width, with adhesive tape on the sides.~2. The LabPatch circuit chip lies on the underside of the bandage. The circuit is in the form of a small chip (approximately 15.7 mm \[0.618\] x 15.7 mm \[0.618\]) placed in contact with the skin. The chip has a telescopic micropipette which draws interstitial fluid to be analyzed for glucose levels. The chip is also able to measure skin temperature to ensure appropriate skin contact.~3. A wire that connects the chip to a laptop that continuously captures glucose data.
Study: NCT01307969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 1,8 mL of the local anesthetic formulations were injected at the apex of the maxillary right canine.
Study: NCT00653822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alefacept
Description: IC and SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alefacept
Description: IC and SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alefacept
Description: IC and SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: IV and SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: IV and SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: IV and SC
Study: NCT04139876

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Haemorrhoidectomy
Description: Patient operated in the lithotomy position. The external components are grasped by clamps using gentle traction. Diathermy is used for dissection and hemostasis. The skin is incised midway to one-third of the distance from the top of the pedicle, thus, minimizing the skin excision. The subdermal fascia continuing into a submucosal fascia covering the internal anal sphincter is identified as are fibers passing between the hemorrhoid (H) and this fascia. The H is dissected free from the underlying internal sphincter in this plane, leaving the sphincter unharmed. The anal mucosa is incised at the transition from anal mucosa to hemorrhoidal mucosa and only anal mucosa overlying the H is excised. Only the caudal part of the H is excised. With the H held with gentle traction it is divided at the anal orifice. There will thus be a residual part of the H intra-anally with its caudal end 1-2 cm proximal to the anal orifice.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LigaSure Hemorrhoidectomy
Description: Patient is operated in the lithotomy position. The main haemorrhoidal (H) masses are identified and delineated. The H are prolapsed out from the anal canal with Allis clamps or similar pick up forceps. Tension is applied to visualise the junction between the nodule and the mucosal wall (internal) or the perianal tissue (external). A small V-shaped anodermal seal is performed by applying the LigaSure (LS) forceps close to the edge of each pile. The seal is then transacted with scissors along the line of coagulum. Care should be taken to limit the amount of tissue removed to minimize the stricture risk. Repeated applications of the device are performed and the excision is continued into the anal canal, lifting the pile from the internal anal sphincter to the level of the vascular pedicle that is finally sealed by LS and divided.
Study: NCT03296046

Intervention type: BIOLOGICAL
Intervention: Blood test
Description: 30 ml
Study: NCT01110200

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADVAIR DISKUS 250/50 mg BID
Description: Fluticasone propionate/salmeterol 250/50 mcg BID in the DISKUS formulation (ADVAIR DISKUS) is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, indicated in the US for the maintenance treatment of airflow obstruction and reducing exacerbations in patients with COPD.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SEREVENT 50 mcg BID
Description: Salmeterol xinafoate Inhalation Powder (SEREVENT DISKUS) is indicated for the long-term, twice-daily (morning and evening), administration in the maintenance treatment of bronchospasm associated with COPD (including emphysema and chronic bronchitis).
Study: NCT02678858

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Social Cognitive and Behavioral Skills Therapy
Description: The Integrated Social Cognitive and Behavioral Skills Therapy (ISST) is a newly developed treatment program. It is based on the Training of Affect Recognition (Wölwer et al. 2005) and common social skills trainings, which are combined in an integrated rather than a sequenced manner. ISST uses both repeated practice and strategy-based training, and consists of 12 individual sessions, 5 group sessions and 1 individual final session over a period of 6 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neurocognitive Remediation Therapy
Description: The Neurocognitive Remediation Program (NCRT) is based on a neurocognitive training already used as active control condition in our earlier studies (Wölwer et al. 2005, Klingberg et al. 2011). The present version of NCRT is matched in dose, mode and scheme of application to the ISST, but differs from the ISST regarding targeted cognitive domains and preferred training strategy (predominantly drill and practice based). The NCRT provides the same amount of group interaction and companionship as well as the same amount of guided community activity as in the ISST, but is structured in such a way that interactional behavior is secondary (e.g. by competition-like tasks rather than cooperative tasks). Thus therapeutic attention and commitment are held constant across study conditions.